AstraZeneca breast cancer pill fails pivotal trial, limiting use

AstraZeneca's investigational breast cancer pill missed its primary endpoint in a pivotal trial, failing to improve outcomes. The result likely restricts the drug's potential market and may impact AstraZeneca's oncology pipeline. The company has not disclosed full data or next steps.